Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Accumulated Expenses (2017 - 2025)

Dianthus Therapeutics has reported Accumulated Expenses over the past 8 years, most recently at $16.0 million for Q3 2025.

  • Quarterly results put Accumulated Expenses at $16.0 million for Q3 2025, up 106.79% from a year ago — trailing twelve months through Sep 2025 was $16.0 million (up 106.79% YoY), and the annual figure for FY2024 was $13.1 million, up 101.01%.
  • Accumulated Expenses for Q3 2025 was $16.0 million at Dianthus Therapeutics, up from $14.0 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for DNTH hit a ceiling of $16.0 million in Q3 2025 and a floor of $1.6 million in Q1 2023.
  • Median Accumulated Expenses over the past 4 years was $6.6 million (2022), compared with a mean of $7.8 million.
  • Biggest five-year swings in Accumulated Expenses: plummeted 75.55% in 2023 and later skyrocketed 273.13% in 2024.
  • Dianthus Therapeutics' Accumulated Expenses stood at $6.6 million in 2022, then dropped by 1.57% to $6.5 million in 2023, then skyrocketed by 101.01% to $13.1 million in 2024, then increased by 22.22% to $16.0 million in 2025.
  • The last three reported values for Accumulated Expenses were $16.0 million (Q3 2025), $14.0 million (Q2 2025), and $8.0 million (Q1 2025) per Business Quant data.